We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health (CVS) Stock Slides as Market Rises: Facts to Know Before You Trade
Read MoreHide Full Article
CVS Health (CVS - Free Report) closed at $82.44 in the latest trading session, marking a -1.03% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.29% for the day. Elsewhere, the Dow saw a downswing of 0.31%, while the tech-heavy Nasdaq appreciated by 0.89%.
The stock of drugstore chain and pharmacy benefits manager has risen by 13.34% in the past month, leading the Medical sector's gain of 0.32% and the S&P 500's gain of 10.54%.
The upcoming earnings release of CVS Health will be of great interest to investors. The company's earnings report is expected on May 6, 2026. The company's upcoming EPS is projected at $2.21, signifying a 1.78% drop compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $94.38 billion, indicating a 0.23% decrease compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $7.14 per share and a revenue of $406.01 billion, indicating changes of +5.78% and +0.98%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for CVS Health. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.04% fall in the Zacks Consensus EPS estimate. CVS Health is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, CVS Health currently has a Forward P/E ratio of 11.66. This represents a discount compared to its industry average Forward P/E of 15.42.
Also, we should mention that CVS has a PEG ratio of 0.87. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical Services industry was having an average PEG ratio of 1.4.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 97, which puts it in the top 40% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
CVS Health (CVS) Stock Slides as Market Rises: Facts to Know Before You Trade
CVS Health (CVS - Free Report) closed at $82.44 in the latest trading session, marking a -1.03% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.29% for the day. Elsewhere, the Dow saw a downswing of 0.31%, while the tech-heavy Nasdaq appreciated by 0.89%.
The stock of drugstore chain and pharmacy benefits manager has risen by 13.34% in the past month, leading the Medical sector's gain of 0.32% and the S&P 500's gain of 10.54%.
The upcoming earnings release of CVS Health will be of great interest to investors. The company's earnings report is expected on May 6, 2026. The company's upcoming EPS is projected at $2.21, signifying a 1.78% drop compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $94.38 billion, indicating a 0.23% decrease compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $7.14 per share and a revenue of $406.01 billion, indicating changes of +5.78% and +0.98%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for CVS Health. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.04% fall in the Zacks Consensus EPS estimate. CVS Health is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, CVS Health currently has a Forward P/E ratio of 11.66. This represents a discount compared to its industry average Forward P/E of 15.42.
Also, we should mention that CVS has a PEG ratio of 0.87. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical Services industry was having an average PEG ratio of 1.4.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 97, which puts it in the top 40% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.